Bridging the Gap: Transforming EU Biotech Policy

ADC and Dansk Bio’s new report reveals what’s holding EU biotech back, and how targeted policy change can close the gap with the US. Key findings span funding shortfalls, translation challenges, and regulatory bottlenecks.

• Funding shortfall: EU pension funds invest 100x less than US peers, costing billions in growth.
• Translation gap: Europe’s top research often fails to scale commercially.
• Regulatory delay: Clinical and drug approvals take up to 40% longer than in the US.

• Align pension fund rules with the US to unleash growth capital
• Build professional translation offices in major EU universities
• Harmonise and speed up regulatory reviews

“Bridging the Gap – Transforming EU Biotech Policy” is a comprehensive mixed-methods analysis conducted by Amsterdam Data Collective (ADC) in collaboration with Dansk Bio, with support from the Novo Nordisk Foundation. The analysis draws on quantitative data from many authoritative sources (OECD, WIPO, Pitchbook, Eurostat, FDA, EMA) and qualitative expert interviews with leading figures in biotech entrepreneurship, venture capital, and innovation policy.

The report was developed to inform policymakers, biotech investors, research institutions, and industry leaders on the structural barriers limiting EU biotech competitiveness – and the specific policy reforms capable of unlocking transformative growth.

Download the full report to understand the complete analysis, data, and policy recommendations. Share these findings with your network of policymakers, investors, and biotech leaders.

For media inquiries, briefings, or expert commentary on EU biotech policy, contact:

Marc Skov Jacobsen
Project Manager, ADC Consulting